Flag of the European Union EU Clinical Trials Register Help

Clinical trials for placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Study title: Clinical Study on the Efficacy and Tolerability of Acarbose (BAY g 5421) Compared with Placeboin Diabetic Children on Conventional Insulin Treatment, in Particular with Observation of the Glycemic Control Index ( PH-24820 )
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_0665_study_synopsis.pdf
    View full study record
    Document reference: 46158
    Study title: Clinical Study to Investigate the Efficacy and Tolerability of Acarbose (BAY g 5421) Versus Placebo in Diabetic Children (PH 23433)
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_0634_study_synopsis.pdf
    View full study record
    Document reference: 46155
    Study title: Double-Blind, Cross-Over Clinical Study at a Single Centre to Compare Acarbose (BAY g 5421) with Placebo in Respect of Efficacy and Tolerability in Patients with Cystic Fibrosis and Pathological Glucose Tolerance (Pilot Study)(PH-26068)
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_0696_study_synopsis.pdf
    View full study record
    Document reference: 46159
    Study title: NON RANDOMISED FOLLW-UP STUDY WITH ACARBOSE-TREATMENT AND PRE- AND AFTER-TREATMENT WITH PLACEBO IN DIABETIC CHILDREN (TYPE I) STUDY 0428 (PH 14352)
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_0428_study_synopsis.pdf
    View full study record
    Document reference: 46156
    Study title: TREATMENT OF CHICKENPOX IN CHILDREN WITH ZOVIRAX SUSPENSION IN A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Active substance: ACICLOVIR
    Study summary document link (including results): Study ZOVIRAX- 183 Aciclovir Oral.xls
    View full study record
    Document reference: 46214
    Study title: A double-blind, multicenter, multi-dose, parallel group, placebo-controlled study on the efficacy and safety of a homeopathic combination remedy vs.placebo over 14 days of treatment in children with acute otitis media.
    Active substance: Aconitum napellus Dil. D6 0,075 ml; Capsicum annuum Dil. D4 0,075 ml; Chamomilla recutita Ø 0,225 ml; Echinacea purpurea Ø 0,75 ml; Hydrargyrum bicyanatum Dil. D6 0,075 ml; Hydrastis canadensis Dil. D4 0,075 ml; Iodum Dil. D4 0,075 ml; Natrium tetraboracicum Dil. D4 0,075 ml; Sambucus nigra Ø 0,225 ml; Sanguinaria canadensis Ø 0,075 ml.
    Study summary document link (including results):
    View full study record
    Document reference: 39772
    Study title: A double-blind, 2 period, cross-over, placebo-controlled study evaluating three daily doses of 4mg BW825C.
    Active substance: ACRIVASTIN
    Study summary document link (including results): Study BW825C31UK-Acrivastine.xls
    View full study record
    Document reference: 46909
    Study title: Gibbs−T−G, McDonnell−K−A, Stokes−T, Graham−A−A. Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonal allergic rhinitis. The British journal of clinical practice, {Br−J−Clin−Pract}, Jan 1989, vol. 43, no. 1, p. 11−4.Gibbs−T−G, McDonnell−K−A, Stokes−T, Graham−A−A. Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonal allergic rhinitis. The British journal of clinical practice, {Br−J−Clin−Pract}, Jan 1989, vol. 43, no. 1, p. 11−4.
    Active substance: ACRIVASTIN
    Study summary document link (including results):
    View full study record
    Document reference: 46224
    Study title: Juhlin−L, Gibson−J−R, Harvey−S−G, Huson−L−W. Acrivastine versus clemastine in the treatment of chronic idiopathic urticaria. A double−blind, placebo−controlled study. International journal of dermatology, {Int−J−Dermatol}, Dec 1987, vol. 26, no. 10, p. 653−4.Juhlin−L, Gibson−J−R, Harvey−S−G, Huson−L−W. Acrivastine versus clemastine in the treatment of chronic idiopathic urticaria. A double−blind, placebo−controlled study. International journal of dermatology, {Int−J−Dermatol}, Dec 1987, vol. 26, no. 10, p. 653−4.
    Active substance: ACRIVASTIN
    Study summary document link (including results):
    View full study record
    Document reference: 46225
    Study title: Medical report of a double-blind, placebo-controlled, crossover study, to evaluate the efficacy and safety of 3 daily doses of 4 mg BW825C in children (6-13 yrs) exhibiting the symptoms of perennial allergic rhinitis, conducted by Dr. E.G. Weinberg, Cape Town, South Africa. Report No. BRAH/85/0011/00
    Active substance: ACRIVASTIN
    Study summary document link (including results): Study H40-082-C86-Acrivastine.xls
    View full study record
    Document reference: 46227
    Study title: clinical study in the report N° FILIRF-FRZ0069-EN-E01: Comparison of oral lysine acetylsalicylate (Aspégic 500 ®) and a buffered aspirin (Bufferin ®) versus placebo for the relief of postoperative pain (3rd molar removal) - JF. Tecucianu, G. Bathelet, G. Narbonne - 1985
    Active substance: ACETYL SALICYLIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 46180
    Study title: Gibbs−T−G, McDonnell−K−A, Stokes−T, Graham−A−A. Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonal allergic rhinitis. The British journal of clinical practice, {Br−J−Clin−Pract}, Jan 1989, vol. 43, no. 1, p. 11−4.Gibbs−T−G, McDonnell−K−A, Stokes−T, Graham−A−A. Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonal allergic rhinitis. The British journal of clinical practice, {Br−J−Clin−Pract}, Jan 1989, vol. 43, no. 1, p. 11−4.
    Active substance: ACRIVASTIN AND PSEUDOEPHEDRINE
    Study summary document link (including results):
    View full study record
    Document reference: 46233
    Study title: Juhlin−L, Gibson−J−R, Harvey−S−G, Huson−L−W. Acrivastine versus clemastine in the treatment of chronic idiopathic urticaria. A double−blind, placebo−controlled study. International journal of dermatology, {Int−J−Dermatol}, Dec 1987, vol. 26, no. 10, p. 653−4.Juhlin−L, Gibson−J−R, Harvey−S−G, Huson−L−W. Acrivastine versus clemastine in the treatment of chronic idiopathic urticaria. A double−blind, placebo−controlled study. International journal of dermatology, {Int−J−Dermatol}, Dec 1987, vol. 26, no. 10, p. 653−4.
    Active substance: ACRIVASTIN AND PSEUDOEPHEDRINE
    Study summary document link (including results):
    View full study record
    Document reference: 46234
    Study title: Latte J et al. A randomized, double-blind, placebo-controlled trial of pseudoephedrine in coryza. Clin Exp Pharmacol Physiol 2004; 31(7): 429-32Latte J et al. A randomized, double-blind, placebo-controlled trial of pseudoephedrine in coryza. Clin Exp Pharmacol Physiol 2004; 31(7): 429-32
    Active substance: ACRIVASTIN AND PSEUDOEPHEDRINE
    Study summary document link (including results):
    View full study record
    Document reference: 25809
    Study title: A phase IV double-blind multicenter study comparing the antipyretic effectiveness of aspirin, acetaminophen, and placebo in febrile children. Stat Rpt 32. Protocol 9-106, Unpublished Report 136.
    Active substance: ACETYL SALICYLIC ACID AND PARACETAMOL
    Study summary document link (including results): acetylsalicylic acid_paracetamol 9-106.pdf
    View full study record
    Document reference: 47203
    Study title: A phase IV double-blind single dose evaluation of the safety and efficacy of acetaminophen 1000 mg, aspirin 650 mg, and placebo in the treatment of pain following oral surgery.
    Active substance: ACETYL SALICYLIC ACID AND PARACETAMOL
    Study summary document link (including results): acetylsalicylic acid_paracetamol 2-231.pdf
    View full study record
    Document reference: 47205
    Study title: A phase IV double-blind single dose study of the efficacy and safety of acetaminophen 1000 mg, aspirin 1000 mg, and placebo in the treatment of pain following oral surgery. Stat Rpt 45. Protocol 3-251, Unpublished Report 157.
    Active substance: ACETYL SALICYLIC ACID AND PARACETAMOL
    Study summary document link (including results): acetylsalicylic acid_paracetamol 3-251.pdf
    View full study record
    Document reference: 47204
    Study title: A phase IV double-blind single dose study of the safety and efficacy of acetaminophen 1000 mg, Gemnisyn® 1300 mg, and placebo in the treatment of pain following oral surgery.
    Active substance: ACETYL SALICYLIC ACID AND PARACETAMOL
    Study summary document link (including results): acetylsalicylic acid_paracetamol 1-220.pdf
    View full study record
    Document reference: 47207
    Study title: Phase IV Double-Blind Single Dose Study of the Safety and Efficacy of Acetaminophen 1000 mg, Aspirin 650 mg, and Placebo in the Treatment of Pain Following Oral Surgery.
    Active substance: ACETYL SALICYLIC ACID AND PARACETAMOL
    Study summary document link (including results): acetylsalicylic acid_paracetamol 1-229.pdf
    View full study record
    Document reference: 47206
    Study title: phase IV double-blind multicenter study comparing the antipyretic effectiveness of aspirin, acetaminophen, choline salicylate and placebo in febrile children.
    Active substance: ACETYL SALICYLIC ACID AND PARACETAMOL AND CHOLINE SALICYLATE
    Study summary document link (including results): acetylsalicylic acid_choline salicylate_paracetamol 118.pdf
    View full study record
    Document reference: 47208
    1  2  3  4  5  6  7  8  9  Next» Last»»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 14:29:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA